Tumor response and clinical benefit in neuroendocrine tumors after 7.4 Gbq 90Y-DOTATOC

Journal of Nuclear Medicine

Volumn 43, Issue 5, 2002, Pages 610-616

  Waldherr, Christian ^a   Pless, Miklos ^a   Maecke, Helmut R ^a   Schumacher, Tilmann ^a   Crazzolara, Armin ^a   Nitzsche, Egbert U ^a   Haldemann, Andreas ^a   Mueller Brand, Jan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

90Y DOTATOC; Neuroendocrine tumor; Octreotide; Radionuclide therapy; Radiopeptide; Somatostatin

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CISPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERFERON; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE; PENTETREOTIDE IN 111; STREPTOZOCIN; YTTRIUM 90;

ADULT; ANEMIA; ARTICLE; BRONCHUS TUMOR; CANCER GRADING; CANCER PAIN; CANCER RADIOTHERAPY; CANCER REGRESSION; CARCINOID SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; EVALUATION; FLUSHING; FOLLOW UP; HUMAN; ISOTOPE LABELING; KIDNEY FAILURE; LYMPHOCYTOPENIA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PELLAGRA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; WHEEZING;

CARCINOID TUMOR; HUMANS; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PAIN, INTRACTABLE; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 0036250672     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Glucagonoma, vipoma, somatostatinoma, other hormones, and nonfunctional tumors
2. Carcinoid tumors and the carcinoid syndrome
3. Endocrine tumors of the pancreas
4. The glucagonoma: Surgically curable diabetes
5. Clinical aspects of glucagon producing islet cell tumors
6. Advances in chemotherapy and biotherapy of endocrine tumors
7. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue
8. Metastatic carcinoid tumors and the malignant carcinoid syndrome
9. Localisation of endocrine related tumors with radioiodinated analogue somatostatin
10. Somatostatin receptor imaging in the localization of neuroendocrine tumors
11. Drug therapy: Octreotide
12. Somatostatin receptors and disease: Role of receptor subtypes
13. New somatostatin analogs for SPET and PET
14. DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC): A unique somatostatin receptor ligand for labeling with a variety of metallic radionuclides
15. 3) octreotide as carriers for somatostatin receptor targeted scintigraphy and radionuclide therapy
16. Radiometal labelled macrocyclic chelator derivatised somatostatin analogue with superb tumor targeting properties and potential for receptor mediated internal radiotherapy
17. DOTATOC: A powerful new tool for receptor mediated radionuclide therapy
18. Yttrium-90 labelled somatostatin-analogue for cancer treatment
19. Yttrium-90 DOTATOC: First clinical results
20. 90Y-DOTATOC) in the treatment of neuroendocrine tumors: A clinical phase II study
21. 3-octreotide, a promising somatostatin analogue for radionuclide therapy
22. 90Y-DOTATOC
23. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system
24. Treatment of the carcinoid syndrome with long acting somatostatin analogue lanreotide: A prospective study in 39 patients
25. Empiric chemotherapy in patients with carcinoma of unknown primary site
26. Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin
27. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin
28. Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin
29. Selective hepatic arterial chemoembolisation for liver metastases in patients with carcinoid tumor or islet cell carcinoma
30. Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors